吡唑并[4,3- b ]嘧啶[4,5- e ] [1,4]二氮杂衍生物作为Aurora A / B和KDR的新型多靶点抑制剂
摘要:
极光A,极光B和包含激酶插入域的受体(KDR)在持续的癌症生长中起重要作用。在本研究中,设计并合成了十八种吡唑并[4,3- b ]嘧啶基[4,5- e ] [1,4]二氮杂derivatives衍生物。大部分制备的化合物都表现出明显的酶促活性(Aurora A / B和KDR)。在这些类似物中,化合物17g表现出显着的Aurora A / B和KDR效能,IC 50值分别为46.2 nM,37.6 nM和21.6 nM。进一步生物学分析的结果表明,化合物17g对SNU-5,MKN-45和MKN-74细胞系具有中等的抗增殖活性,在MKN-45,MKN-74,SGC-7901和SNU-5细胞系中诱导G2 / M细胞周期阻滞和凋亡。可接受的药代动力学特征(F = 63.8%),并抑制了小鼠体内SNU-5肿瘤的增殖。以上所有结果均表明吡唑并[4,3- b ]嘧啶基[4,5- e ] [1,4]二氮杂可以开发为多种Aurora
Diamino pyrazols, their synthesis, keratin fibre dyeing compositions
申请人:L'Oreal
公开号:US06118008A1
公开(公告)日:2000-09-12
The invention discloses new 5-substituted 3,4-diamino pyrazols, their methods of preparation, compositions for keratin fiber oxidation dyeing containing them as an oxidizing base, and the dyeing methods using same.
[EN] CYCLIC COMPOUNDS AND METHODS OF USING SAME<br/>[FR] COMPOSÉS CYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION
申请人:SCHRODINGER INC
公开号:WO2021134004A1
公开(公告)日:2021-07-01
The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof which are MALT1 inhibitors. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and pharmaceutically acceptable salts thereof, and methods of using the compounds and compositions for treating diseases, such as cancer, autoimmune disorders, and inflammatory disorders.
[EN] PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN<br/>[FR] DÉRIVÉS DE PYRAZOLO[1,5-A]PYRIMIDINE AYANT UNE ACTIVITÉ MULTIMODALE CONTRE LA DOULEUR
申请人:ESTEVE PHARMACEUTICALS SA
公开号:WO2021239558A1
公开(公告)日:2021-12-02
The present invention relates to pyrazolopyrimidine derivatives having dual pharmacological activity towards both the α2δ subunit of the voltage-gated calcium channel and the sigma-1 (σ1) receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.